CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase II Study of Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06654050
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:12.771686+00:00
- Published At
- 2026-03-17T00:00:00+00:00
- Record Updated At
- 2026-03-17
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Mesothelioma", "Malignant Mesothelioma (MM)", "Early-stage Mesothelioma", "Subclinical Mesothelioma", "BRCA1-Associated Protein-1 (BAP1) Mutations", "Early-stage BAP1-associated Malignancies"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-17"- protocolSection.identificationModule.nctId
"NCT06654050"- protocolSection.identificationModule.officialTitle
"Phase II Study of Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.